Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new care pathway speed up advanced heart failure decisions?

NCT ID NCT07826078

Disease control Sponsor: CardioVision International Tech, S.A.S. de C.V. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether a standardized care pathway helps adults with advanced heart failure in Latin America complete a multidisciplinary evaluation and receive a documented treatment decision within 90 days. The trial includes 360 adults with acquired or structural heart disease who may need heart transplantation, mechanical circulatory support, or other advanced therapies. Clinics switch from their usual local approach to the TORCH pathway in stages, and the study tracks how many patients complete evaluations, reach authorized treatment pathways, and what clinical outcomes follow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a standardized health-services pathway for advanced heart failure care
What this could lead to
If the pathway works, it could help more adults with advanced heart failure get timely evaluations and reach authorized treatment options such as transplantation or mechanical support.
What could go wrong
This is a health-services trial, not a new drug or device, so it cannot cure heart failure. Results may not apply outside Latin America, and better coordination does not guarantee that organs or advanced therapies become available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 360 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2027

An estimate. Start dates often move.

Expected to finish

Mar 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult aged 18 years or older at informed consent. * Documented acquired or structural heart disease with advanced heart failure meeting a protocol-defined trigger for specialized advanced-therapy evaluation. * Identification within an activated TORCH network cluster with an operational route to at least one authorized advanced-therapy or transplant center. * Ability to complete protocol-defined follow-up directly or through an authorized network pathway. * Provision of informed consent according to applicable requirements. Exclusion Criteria: * Congenital heart disease as the primary condition, or absence of a documented pathophysiological relationship between acquired or structural heart disease and advanced heart failure. * No authorized route for protocol evaluation or follow-up at the time of enrollment. * Unable or unwilling to provide informed consent when required. * The prespecified multidisciplinary evaluation and advanced-pathway decision were already completed and remain clinically current before enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired heart disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

advanced heart failure heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acquired heart disease Advanced heart failure Heart transplantation Mechanical circulatory support Structural heart disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.